Comparative Pharmacology
Head-to-head clinical analysis: COPEGUS versus VEKLURY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COPEGUS versus VEKLURY.
COPEGUS vs VEKLURY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ribavirin is a nucleoside analogue that inhibits viral RNA synthesis by interfering with RNA capping and polymerase activity, and may also modulate immune responses.
Remdesivir is a nucleotide analog prodrug that, after intracellular metabolism, incorporates into nascent viral RNA chains causing synthesis termination and inhibition of RNA-dependent RNA polymerase (RdRp). It targets the SARS-CoV-2 RdRp with selectivity over human RNA polymerases.
800 mg orally twice daily to 1200 mg orally twice daily based on body weight (≤75 kg: 800 mg; >75 kg: 1200 mg), in combination with ribavirin, for 24 to 48 weeks depending on genotype.
200 mg IV on Day 1, then 100 mg IV once daily for 5 to 10 days.
None Documented
None Documented
Terminal elimination half-life is approximately 120-170 hours following multiple doses, supporting once-daily dosing with prolonged viral suppression.
Remdesivir: ~1 hour (parent); GS-441524: ~27 hours (terminal). Context: GS-441524 accumulation may occur with daily dosing.
Ribavirin is primarily eliminated renally as unchanged drug (61%) and metabolites (30%); biliary/fecal excretion accounts for ~9%.
Renal: 10% unchanged remdesivir; 49% as metabolite GS-441524; 18% as other metabolites. Fecal: 47.5% as metabolites. Biliary: minor.
Category C
Category C
Antiviral
Antiviral